mTORC1 regulates the metabolic switch of postnatal cardiomyocytes during regeneration

Wyatt G Paltzer1, Timothy J Aballo1, Jiyoung Bae2

  • 1Department of Cell and Regenerative Biology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, United States.

Insights

Inhibition of mechanistic target of rapamycin complex 1 (mTORC1) in neonatal hearts accelerates metabolic maturation, hindering heart regeneration. This suggests mTORC1 is crucial for maintaining the regenerative capacity of the neonatal heart.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Regulation
  • Developmental Biology

Background:

  • Postnatal cardiomyocytes shift from glycolysis to fatty acid oxidation, reducing cardiac regenerative potential.
  • The role of mechanistic target of rapamycin complex 1 (mTORC1) in this metabolic switch and heart regeneration is unclear.

Purpose of the Study:

  • To define the role of mTORC1 in postnatal heart development, metabolic maturation, and regeneration.
  • To investigate mTORC1's impact on cardiomyocyte proliferation and cardiac repair following injury.

Main Methods:

  • Immunoblotting
  • Rapamycin and everolimus treatment
  • Myocardial infarction model
  • Global quantitative proteomics

Main Results:

  • mTORC1 activity is dynamically regulated in regenerating versus non-regenerating hearts.
  • Acute mTORC1 inhibition by rapamycin/everolimus reduced cardiomyocyte proliferation and neonatal heart regeneration.
  • Proteomic analysis showed mTORC1 inhibition shifted neonatal injured hearts from glycolysis to fatty acid oxidation, accelerating metabolic maturation.

Conclusions:

  • mTORC1 inhibition accelerates the postnatal metabolic switch, impeding cardiomyocyte proliferation and heart regeneration.
  • mTORC1 plays a critical role in regulating postnatal cardiac metabolism and may be a therapeutic target for promoting heart regeneration.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tissue Renewal without Stem Cells01:23

Tissue Renewal without Stem Cells

After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...